The efficacy of clopidogrel plus aspirin vs aspirin alone were consistent between patients with and without intracranial arterial stenosis (ICAS), in the Clopidogrel in High Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) trial.
Results indicated higher rate of recurrent stroke in minor stroke or high risk TIA patients with ICAS than in those without.
There was no significant difference in the response to the 2 antiplatelet therapies between patients with and without ICAS in the CHANCE trial.
Dual antiplatelet therapy in stroke and ICAS
Liu L, et al.